Cabozantinib unlikely to be recommended based on cost: NICE and Ipsen in talks

NICE and Ipsen are continuing to discuss whether cabozantinib (Cabometyx) is to be recommended for use on the NHS in England and Wales. Cabozantinib, a next generation tyrosine kinase inhibitor for use in advanced kidney cancer, has been shown to increase overall and progression-free survival compared to everolimus in the recent METEOR trial.
The latest report published by NICE this week was a second Appraisal Consultation Document (ACD) consultation document within which NICE have suggested that cabozantinib is unlikely to be recommended based on its cost effectiveness rating (QUALY). However, a similar situation occurred at this point in the appraisal of nivolumab and it went on to be recommended.
So all is not lost and we are pleased to see Ipsen and NICE are talking at the table and hope to see a positive outcome for kidney cancer patients later in the year.